Drug
Glasdegib clinical trials
Also written PF-04449913 and Daurismo.
- studies test it
- 22
- open now
- 0
- in phase 3
- 4
- first study started
- 2010
How studies write it
Studies that test it under each name
Name
Brand
Development codes
Combined with it in one product
Studies by the year they started
22 studies that test it; most in 2018 (4)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2015 | 2 |
| 2017 | 3 |
| 2018 | 4 |
| 2019 | 3 |
| 2020 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 10
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 11 · Other 11
Pfizer (11) · University of California, Irvine (1) · Institut National de la Santé Et de la Recherche Médicale, France (1) · University of Nebraska (1) · Grupo Español de Investigación en Neurooncología (1) · M.D. Anderson Cancer Center (1) · University of Colorado, Denver (1) · H. Lee Moffitt Cancer Center and Research Institute (1)
Often tested with
Tested in the same studies.
Azacitidine (5) · CPX-351 (2) · Cytarabine (2) · Decitabine (2) · Venetoclax (2) · Nilotinib (1) · Ceritinib (1) · Capmatinib (1)
Studies
Open first, then newest update. How each study uses glasdegib is read from its arms, and is right about nine times in ten.
Testing it · 22
- CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid LeukemiaActive, not recruitingPhase 2University of California, IrvineNCT04231851Written as Glasdegib
- Molecular Profiling of Advanced Soft-tissue SarcomasCompletedPhase 3Institut National de la Santé Et de la Recherche Médicale, FranceNCT03784014Written as Glasdegib
- Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid LeukemiaCompletedPhase 2University of NebraskaNCT03226418Written as glasdegib
- Glasdegib for Chronic Graft-Versus-Host DiseaseTerminatedPhase 1/2Fred Hutchinson Cancer CenterNCT04111497Written as Glasdegib
- A Study Of PF-04449913 In Select Hematologic MalignanciesCompletedPhase 1PfizerNCT00953758Written as PF-04449913
- Glasdegib (PF-04449913) With Temozolomide Newly Diagnosed GlioblastomaCompletedPhase 1/2Grupo Español de Investigación en NeurooncologíaNCT03466450Written as PF-04449913
- A Study Of PF-04449913 Administered Alone In Select Solid TumorsCompletedPhase 1PfizerNCT01286467Written as PF-04449913
- A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In Untreated MDS, AML and CMML PatientsCompletedPhase 1PfizerNCT02367456Written as PF-04449913 (Glasdegib)
- Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMMLCompletedPhase 3PfizerNCT04842604Written as Glasdegib
- OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid LeukemiaCompletedPhase 1/2M.D. Anderson Cancer CenterNCT03390296Written as Glasdegib
- A Study Evaluating Intensive Chemotherapy With or Without Glasdegib or Azacitidine With or Without Glasdegib In Patients With Previously Untreated Acute Myeloid LeukemiaCompletedPhase 3PfizerNCT03416179Written as glasdegib
- Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia)TerminatedPhase 3University Hospital HeidelbergNCT04093505Written as Glasdegib
- Glasdegib in Refractory Patients With Sclerotic Chronic Graft-Versus-Host DiseaseStatus unknownPhase 1/2Grupo Espanol de trasplantes hematopoyeticos y terapia celularNCT03415867Written as Glasdegib
- PF-04449913 For Patients With Acute Myeloid Leukemia at High Risk of Relapse After Donor Stem Cell TransplantCompletedPhase 2University of Colorado, DenverNCT01841333Written as PF-04449913
- GLAD-AML - Glasdegib (Pf-04449913) With Two Standard Decitabine Regimens for Older Patients With Poor-risk Acute Myeloid LeukemiaTerminatedPhase 2Yale UniversityNCT04051996Written as Glasdegib
- Phase II Hedgehog Inhibitor for Myelodysplastic Syndrome (MDS)CompletedPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT01842646Written as PF-04449913
- A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of GlasdegibCompletedPhase 1PfizerNCT03627754Written as Glasdegib 100 mg single oral dose
- Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With RuxolitinibTerminatedPhase 2PfizerNCT02226172Written as Glasdegib (PF-04449913)
- Glasdegib Absolute Bioavailability StudyCompletedPhase 1PfizerNCT03270878Written as Glasdegib Oral Tablet
- Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib PharmacokineticsCompletedPhase 1PfizerNCT02430545Written as Glasdegib
See all 22 studies that test glasdegib →
Given in every arm · 4 — glasdegib is usual care beside what is tested
- A Study Of PF-04449913 In Japanese Patients With Select Hematologic MalignanciesCompletedPhase 1PfizerNCT02038777Written as PF-04449913
- Glasdegib-Based Treatment Combinations for the Treatment of Patients With Relapsed Acute Myeloid Leukemia Who Have Undergone Hematopoietic Cell TransplantationWithdrawnPhase 1City of Hope Medical CenterNCT04655391Written as Glasdegib Maleate
- A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedPhase 2PfizerNCT01546038Written as PF-04449913
- A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH FormulationCompletedPhase 1PfizerNCT03130556Written as Glasdegib
Codes
What other systems call glasdegib · ClinicalTrials.gg INT000103
- MeSH (NLM) C000592580glasdegibOne source NLM
- UNII (FDA) K673DMO5H9GLASDEGIBConfirmed FDA, NLM, Wikidata
- RxNorm 2105845Confirmed FDA, Wikidata
- Wikidata Q27077810glasdegibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C84862GlasdegibOne source FDA
- DrugBank DB11978One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000592580 | glasdegib | One source NLM |
| UNII (FDA) | K673DMO5H9 | GLASDEGIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2105845 | — | Confirmed FDA, Wikidata |
| Wikidata | Q27077810 | glasdegib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C84862 | Glasdegib | One source FDA |
| DrugBank | DB11978 | — | One source Wikidata |
Also registered as glasdegib maleate (UNII TH2EV99S4Z · RxNorm 2105844).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.